Bredin Prat advises Sanofi as it buys back shares from its shareholder L’Oréal

Bredin Prat is advising Sanofi as it buys back 2.3% of its own shares from its shareholder L’Oréal for a consideration of €3 billion.

For Sanofi, the buy-back involves the acquisition of 29,556,650 shares at a price of €101.50 per share, which represents a 2.8% discount to the closing share price on 31 January 2025.

The acquisition of these shares is expected to have an accretive effect on Sanofi’s earnings per share, thus contributing to increasing shareholder value.

After the transaction, and excluding treasury shares, L’Oréal will own 7.2% of Sanofi’s share capital and 13.1% of its voting rights.

The transaction, which is expected to be finalised in the coming days, is not subject to any specific conditions and was approved on 2 February by Sanofi’s Board of Directors.

The Bredin Prat team advising Sanofi is as follows:

• Corporate: Olivier Assant and Myriam Epelbaum (partners), Armance Amadieu